Interaction between Tafamidis and Ozanimod
Major Others

ID DDInter1737 and DDInter1376
Interaction Coadministration with breast cancer resistance protein (BCRP) inhibitors may increase the exposure of the active metabolites of ozanimod and the risk of adverse effects. Coadministration with cyclosporine, a BCRP inhibitor, did not alter the AUC of ozanimod, but it did double the exposure of the minor active metabolites of ozanimod, RP101988 and RP101075 which are direct precursors of the major active metabolite CC112273.
Management According to the manufacturer, coadministration of ozanimod with BCRP inhibitors is not recommended.
References
Alternative for Tafamidis N07X
Inotersen
Amifampridine
Tetrabenazine
Riluzole
Sodium oxybate
Dalfampridine
Valbenazine
Alternative for Ozanimod L04A
Alefacept
Muromonab
Canakinumab
Certolizumab pegol
Cladribine
Efalizumab
Antithymocyte immunoglobulin (rabbit)
Secukinumab
Brodalumab
Natalizumab
Azathioprine
More

Potential Metabolism Interactions

Substrate-Substrate Interaction：If more than one drug is metabolized by the same CYP, it is possible that its metabolism is inhibited because of the competition between the drugs. That means, it can be useful to lower the dosage of the drugs in the drug-cocktail because they remain longer in the organism than in monotherapy.
Inhibitor-Inhibitor Interaction：Combining two or more inhibitors of one CYP, should be compensated by lowering the dosage of these drugs because the metabolism is reduced and the drugs remain longer in the organism than in monotherapy. Not adapting the dosage bears the risk of even more side effects.
Inhibitor-Substrate Interaction：Combining drugs that have inhibitory effect and are substrates of one particular CYP, should be compensated by lowering the dosage. They rest longer in the organism than in monotherapy. Not adapting the dosage bears the risk of even more side effects.